Sanofi announced its second quarter results on July 25th, with sales of 10.75 billion euros and an estimated 10.42 billion euros. Net sales of Dupixent products in the second quarter were 3.3 billion euros, with an estimated 3.16 billion euros; Beyfortus has a net sales revenue of 18 million euros, with an estimated 14.5 million euros; Aubagio's net sales amounted to 107 million euros, estimated at 88.4 million euros; Vaccine sales of 1.14 billion euros, expected to reach 1.1 billion euros; Flu vaccine sales amounted to 115 million euros, with an estimated 97.8 million euros; The net sales of biopharmaceuticals are 9.44 billion euros, with an estimated 9.1 billion euros.